FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136670246> ?p ?o ?g. }

• W3136670246 endingPage "456" @default.
• W3136670246 startingPage "447" @default.
• W3136670246 abstract "Patients with intermediate-risk non-muscle-invasive bladder cancer (NMIBC) may pose a clinical dilemma without an agreed evidence-based decision tree for personalized treatment.To perform a systematic review and network meta-analysis (NMA) to summarize available evidence on the oncologic outcomes of intravesical therapy in patients with intermediate-risk NMIBC.The MEDLINE, EMBASE, and ClinicalTrials.gov databases were searched in October 2020 according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement. Studies were deemed eligible if they reported on oncologic outcomes in patients with intermediate-risk NMIBC treated with transurethral resection of bladder tumor with and without intravesical chemotherapy or bacillus Calmette-Guérin (BCG) immunotherapy.Twelve studies were included in a qualitative synthesis (systematic review); three were deemed eligible for a quantitative synthesis (NMA). An NMA of five different regimens was conducted for the association of treatment with the 5-yr recurrence risk. Chemotherapy with maintenance was associated with a lower likelihood of 5-yr recurrence than chemotherapy without maintenance (odds ratio [OR] 0.51, 95% credible interval [CI] 0.26-1.03). Immunotherapy, regardless of whether a full- or reduced-dose regimen, was not associated with a significantly lower likelihood of 5-yr recurrence when compared with chemotherapy without maintenance (OR 0.90, 95% CI 0.39-2.11 vs OR 0.93, 95% CI 0.40-2.19). Analysis of the treatment ranking revealed that chemotherapy with maintenance had the lowest 5-yr recurrence risk (P score 0.9666).Our analysis indicates that chemotherapy with a maintenance regimen confers a superior oncologic benefit in terms of 5-yr recurrence risk compared to chemotherapy without maintenance in patients with intermediate-risk NMIBC. Regardless of the dose regimen, immunotherapy with BCG does not appear to be superior to chemotherapy in patients with intermediate-risk NMIBC in term of disease recurrence. However, owing to the lack of comparative studies, there is an unmet need for well-designed, large-scale trials to validate our findings and generate robust evidence on disease recurrence and progression.A maintenance schedule of chemotherapy reduces the rate of long-term recurrence of bladder cancer that has not invaded the bladder muscle. Chemotherapy inserted directly into the bladder and immunotherapy without maintenance schedules seem to have limited benefit in preventing cancer recurrence." @default.
• W3136670246 created "2021-03-29" @default.
• W3136670246 creator A5001883861 @default.
• W3136670246 creator A5004447117 @default.
• W3136670246 creator A5011013432 @default.
• W3136670246 creator A5014044970 @default.
• W3136670246 creator A5030402975 @default.
• W3136670246 creator A5032679795 @default.
• W3136670246 creator A5038866794 @default.
• W3136670246 creator A5046766765 @default.
• W3136670246 creator A5048506098 @default.
• W3136670246 creator A5058063575 @default.
• W3136670246 creator A5070609478 @default.
• W3136670246 creator A5071129858 @default.
• W3136670246 creator A5074919720 @default.
• W3136670246 creator A5075113407 @default.
• W3136670246 creator A5079401169 @default.
• W3136670246 creator A5083351538 @default.
• W3136670246 creator A5087973088 @default.
• W3136670246 date "2022-03-01" @default.
• W3136670246 modified "2023-10-18" @default.
• W3136670246 title "Intravesical Therapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis of Disease Recurrence" @default.
• W3136670246 cites W1572827793 @default.
• W3136670246 cites W1617328014 @default.
• W3136670246 cites W1754265771 @default.
• W3136670246 cites W1850920502 @default.
• W3136670246 cites W1863201015 @default.
• W3136670246 cites W1983160910 @default.
• W3136670246 cites W2010699829 @default.
• W3136670246 cites W2017306423 @default.
• W3136670246 cites W2030874794 @default.
• W3136670246 cites W2039218197 @default.
• W3136670246 cites W2052562958 @default.
• W3136670246 cites W2084541908 @default.
• W3136670246 cites W2108974158 @default.
• W3136670246 cites W2111999709 @default.
• W3136670246 cites W2115135540 @default.
• W3136670246 cites W2132952780 @default.
• W3136670246 cites W2134589781 @default.
• W3136670246 cites W2137442303 @default.
• W3136670246 cites W2161817962 @default.
• W3136670246 cites W2163823502 @default.
• W3136670246 cites W2327257129 @default.
• W3136670246 cites W2418128236 @default.
• W3136670246 cites W2443056117 @default.
• W3136670246 cites W2570682666 @default.
• W3136670246 cites W2735990769 @default.
• W3136670246 cites W2756190798 @default.
• W3136670246 cites W2767594459 @default.
• W3136670246 cites W2805724944 @default.
• W3136670246 cites W2888414785 @default.
• W3136670246 cites W2889646458 @default.
• W3136670246 cites W2894038090 @default.
• W3136670246 cites W2896913775 @default.
• W3136670246 cites W2901729862 @default.
• W3136670246 cites W2911188335 @default.
• W3136670246 cites W2969983122 @default.
• W3136670246 cites W2975497362 @default.
• W3136670246 cites W3016548776 @default.
• W3136670246 cites W3032934787 @default.
• W3136670246 cites W3041863946 @default.
• W3136670246 doi "https://doi.org/10.1016/j.euf.2021.03.016" @default.
• W3136670246 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33762203" @default.
• W3136670246 hasPublicationYear "2022" @default.
• W3136670246 type Work @default.
• W3136670246 sameAs 3136670246 @default.
• W3136670246 citedByCount "3" @default.
• W3136670246 countsByYear W31366702462022 @default.
• W3136670246 countsByYear W31366702462023 @default.
• W3136670246 crossrefType "journal-article" @default.
• W3136670246 hasAuthorship W3136670246A5001883861 @default.
• W3136670246 hasAuthorship W3136670246A5004447117 @default.
• W3136670246 hasAuthorship W3136670246A5011013432 @default.
• W3136670246 hasAuthorship W3136670246A5014044970 @default.
• W3136670246 hasAuthorship W3136670246A5030402975 @default.
• W3136670246 hasAuthorship W3136670246A5032679795 @default.
• W3136670246 hasAuthorship W3136670246A5038866794 @default.
• W3136670246 hasAuthorship W3136670246A5046766765 @default.
• W3136670246 hasAuthorship W3136670246A5048506098 @default.
• W3136670246 hasAuthorship W3136670246A5058063575 @default.
• W3136670246 hasAuthorship W3136670246A5070609478 @default.
• W3136670246 hasAuthorship W3136670246A5071129858 @default.
• W3136670246 hasAuthorship W3136670246A5074919720 @default.
• W3136670246 hasAuthorship W3136670246A5075113407 @default.
• W3136670246 hasAuthorship W3136670246A5079401169 @default.
• W3136670246 hasAuthorship W3136670246A5083351538 @default.
• W3136670246 hasAuthorship W3136670246A5087973088 @default.
• W3136670246 hasBestOaLocation W31366702461 @default.
• W3136670246 hasConcept C121608353 @default.
• W3136670246 hasConcept C126322002 @default.
• W3136670246 hasConcept C141071460 @default.
• W3136670246 hasConcept C143998085 @default.
• W3136670246 hasConcept C156957248 @default.
• W3136670246 hasConcept C2776694085 @default.
• W3136670246 hasConcept C2780352672 @default.
• W3136670246 hasConcept C2781413609 @default.
• W3136670246 hasConcept C71924100 @default.
• W3136670246 hasConcept C95190672 @default.

• next